310 related articles for article (PubMed ID: 18551855)
21. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
Baskaran ND; Gan GG; Adeeba K
Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
[TBL] [Abstract][Full Text] [Related]
22. Advances in management of low-risk febrile neutropenia.
Teuffel O; Sung L
Curr Opin Pediatr; 2012 Feb; 24(1):40-5. PubMed ID: 22037219
[TBL] [Abstract][Full Text] [Related]
23. Management of febrile neutropenia in pediatric oncology patients: a Canadian survey.
Boragina M; Patel H; Reiter S; Dougherty G
Pediatr Blood Cancer; 2007 May; 48(5):521-6. PubMed ID: 16724314
[TBL] [Abstract][Full Text] [Related]
24. Outpatient treatment with intravenous antimicrobial therapy and oral levofloxacin in patients with febrile neutropenia and hematological malignancies.
Bellesso M; Costa SF; Pracchia LF; Santos Dias LC; Chamone D; Dorlhiac-Llacer PE
Ann Hematol; 2011 Apr; 90(4):455-62. PubMed ID: 20852999
[TBL] [Abstract][Full Text] [Related]
25. Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies.
Feld R; Paesmans M; Freifeld AG; Klastersky J; Pizzo PA; Rolston KV; Rubenstein E; Talcott JA; Walsh TJ; ;
Clin Infect Dis; 2002 Dec; 35(12):1463-8. PubMed ID: 12471564
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic risk factors for serious complications in an inpatient population with neutropenia at the onset of a febrile episode].
Gómez Roca C; Rivero M; Hugo K; Novillo A; Marta Lapadula M; Recondo G; Milberg M
Medicina (B Aires); 2006; 66(5):385-91. PubMed ID: 17137166
[TBL] [Abstract][Full Text] [Related]
27. First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study.
Brack E; Bodmer N; Simon A; Leibundgut K; Kühne T; Niggli FK; Ammann RA
Pediatr Blood Cancer; 2012 Sep; 59(3):423-30. PubMed ID: 22271702
[TBL] [Abstract][Full Text] [Related]
28. Outpatient management of febrile neutropenia: is it safe yet?
Johnson TN; DeJesus YA; McMahon L; Rolston KV; Row MB
J Support Oncol; 2008; 6(5):219-20. PubMed ID: 18551857
[No Abstract] [Full Text] [Related]
29. [Febrile neutropenia].
Bally F; Marchetti O; Cometta A
Rev Prat; 2003 Dec; 53(19):2101-7. PubMed ID: 15008466
[TBL] [Abstract][Full Text] [Related]
30. A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer.
Akova M; Paesmans M; Calandra T; Viscoli C;
Clin Infect Dis; 2005 Jan; 40(2):239-45. PubMed ID: 15655741
[TBL] [Abstract][Full Text] [Related]
31. Outpatient high-dose melphalan in multiple myeloma patients.
Kassar M; Medoff E; Seropian S; Cooper DL
Transfusion; 2007 Jan; 47(1):115-9. PubMed ID: 17207239
[TBL] [Abstract][Full Text] [Related]
32. [Consensus: Rational approach towards the patient with cancer, fever and neutropenia].
Santolaya ME; Rabagliati R; Bidart T; Payá E; Guzmán AM; Morales R; Braun S; Bronfman L; Ferrés M; Flores C; García P; Letelier LM; Puga B; Salgado C; Thompson L; Tordecilla J; Zubieta M; ;
Rev Chilena Infectol; 2005; 22 Suppl 2():S79-113. PubMed ID: 16311689
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of guideline for treatment of febrile neutropenia in pediatric cancer at Siriraj Hospital.
Sanpakit K; Phuakpet K; Veerakul G; Narkbunnam N; Chokephaibulkit K
J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S124-34. PubMed ID: 16858853
[TBL] [Abstract][Full Text] [Related]
34. Safety and costs of treating neutropenic fever in an outpatient setting.
Del Prete SA; Ryan SP; Jacobson JS; Erichson RB; Weinstein PL; Grann VR
Conn Med; 1999 Dec; 63(12):713-7. PubMed ID: 10659471
[TBL] [Abstract][Full Text] [Related]
35. Risk assessment and treatment of low-risk patients with febrile neutropenia.
Kern WV
Clin Infect Dis; 2006 Feb; 42(4):533-40. PubMed ID: 16421798
[TBL] [Abstract][Full Text] [Related]
36. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia.
Donohue R
Oncol Nurs Forum; 2006 Nov; 33(2):347-52. PubMed ID: 16518450
[TBL] [Abstract][Full Text] [Related]
37. Outpatient Management of Febrile Neutropenia: Should We Change the Standard of Care?
Talcott JA
Oncologist; 1997; 2(6):365-373. PubMed ID: 10388071
[TBL] [Abstract][Full Text] [Related]
38. [Febrile neutropenia in the child with cancer. Current concepts about risk assessment and selective management].
Santolaya ME
Rev Med Chil; 2001 Dec; 129(12):1449-54. PubMed ID: 12080883
[TBL] [Abstract][Full Text] [Related]
39. Is it time to redefine the management of febrile neutropenia in cancer patients?
Anaissie EJ; Vadhan-Raj S
Am J Med; 1995 Mar; 98(3):221-3. PubMed ID: 7872336
[No Abstract] [Full Text] [Related]
40. The outpatient management of febrile neutropenia in cancer patients.
Freifeld AG; Pizzo PA
Oncology (Williston Park); 1996 Apr; 10(4):599-606, 611-2; discussion 615-6. PubMed ID: 8723296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
